Portland Global Advisors LLC Holds Stake in Gilead Sciences Inc. (GILD)
Portland Global Advisors LLC continued to hold its position in Gilead Sciences Inc. (NASDAQ:GILD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,478 shares of the biopharmaceutical company’s stock at the end of the second quarter. Portland Global Advisors LLC’s holdings in Gilead Sciences were worth $290,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in GILD. Joel Isaacson & Co. LLC raised its position in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares in the last quarter. Loomis Sayles & Co. L P raised its position in shares of Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares in the last quarter. Jolley Asset Management LLC raised its position in shares of Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 682 shares in the last quarter. North Star Investment Management Corp. raised its position in shares of Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 700 shares in the last quarter. Finally, Peoples Financial Services CORP. raised its position in shares of Gilead Sciences by 30.4% in the second quarter. Peoples Financial Services CORP. now owns 2,575 shares of the biopharmaceutical company’s stock valued at $215,000 after buying an additional 600 shares in the last quarter. Institutional investors and hedge funds own 77.94% of the company’s stock.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.27% during midday trading on Friday, reaching $75.24. 11,149,150 shares of the company’s stock were exchanged. Gilead Sciences Inc. has a 12-month low of $74.92 and a 12-month high of $111.11. The stock’s 50 day moving average is $78.95 and its 200-day moving average is $85.05. The stock has a market cap of $99.29 billion, a PE ratio of 6.60 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping the consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. During the same quarter in the previous year, the firm earned $3.15 earnings per share. The company’s quarterly revenue was down 5.7% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences Inc. will post $11.76 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 2.50%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
Several equities analysts have recently weighed in on the stock. Piper Jaffray Cos. set a $108.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Sunday, August 21st. Jefferies Group reiterated a “hold” rating and set a $96.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 29th. RBC Capital Markets reiterated an “outperform” rating and set a $105.00 price objective (down previously from $120.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Leerink Swann reiterated an “outperform” rating and set a $127.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 29th. Finally, Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, September 26th. Ten equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $104.71.
In other news, Director Kevin E. Lofton sold 3,500 shares of the business’s stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total value of $286,895.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $79.81, for a total transaction of $159,620.00. Following the completion of the transaction, the executive vice president now directly owns 64,122 shares in the company, valued at approximately $5,117,576.82. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.